Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has shared an announcement.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has reported progress in its late-stage clinical program for IMM01 (Timdarpacept), an innovative CD47-targeting SIRPα-Fc fusion protein and the company’s core product, which has been engineered to activate macrophages while avoiding red blood cell binding and has secured orphan-drug designation from the U.S. FDA for first-line treatment of chronic myelomonocytic leukemia (CMML) when combined with azacitidine. The company has completed enrollment of 104 patients in its Phase III trial of IMM01 for first-line CMML as of December 31, 2025, and expects to reach the 132 patients required for interim analysis by the end of March 2026, while stating that its business operations and clinical development remain normal with no material adverse changes, underscoring continued operational stability as it advances a key asset with potential to strengthen its position in the global immuno-oncology market.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a China-based biopharmaceutical company focused on the research and development of innovative immuno-oncology therapies. Its core pipeline centers on IMM01 (Timdarpacept), a first-in-class SIRPα-Fc fusion protein targeting CD47, with global intellectual property and commercial rights and issued patents in China, the United States, Japan and the European Union. The company’s lead indication priority is chronic myelomonocytic leukemia (CMML), where IMM01 is being developed for first-line treatment, including in combination with azacitidine, a regimen that has received U.S. FDA orphan-drug designation.
Average Trading Volume: 1,558,659
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.8B
For an in-depth examination of 1541 stock, go to TipRanks’ Overview page.